Cytosorbents Corporation (CTSO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cytosorbents Corporation (CTSO) Healthcare & Pipeline Overview

Cytosorbents Corporation develops and commercializes blood purification technologies, primarily through its CytoSorb device, used in critical care and organ transplantation. With a focus on cytokine removal and blood compatibility, the company operates within the medical device sector, targeting sepsis, critical illnesses, and complications related to surgery and transplants.

What Is the Investment Thesis for CTSO?

Cytosorbents Corporation presents a high-risk, high-reward investment opportunity within the medical device sector. The company's core value driver is the continued adoption and expansion of CytoSorb in critical care settings. Key growth catalysts include securing regulatory approvals in new geographies and expanding the device's application to new indications. The company's gross margin of 71.5% indicates strong pricing power. However, the company's market cap of $20.0M and negative profit margin of -22.1% highlight the financial risks. The company's success hinges on demonstrating clinical efficacy and achieving profitability.

Based on FMP financials and quantitative analysis

CTSO Key Highlights

Market Cap of $20.0M reflects the company's small size and growth potential within the medical device market.

• Gross Margin of 71.5% indicates strong pricing power and efficient manufacturing processes.
• Profit Margin of -22.1% highlights the company's current lack of profitability, requiring close monitoring of cost management and revenue growth.
• The company has 149 employees, reflecting its operational scale and resource allocation.
• The company's Beta of 1.48 indicates that the stock is more volatile than the market, reflecting its growth-oriented nature and sensitivity to market fluctuations.

Who Are CTSO's Competitors?

CTSO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CTSO's Key Strengths?

Proprietary blood purification technology.

• Established brand recognition with CytoSorb.
• Gross margin of 71.5% indicates strong pricing power.
• Diverse product pipeline targeting various critical care applications.

What Are CTSO's Weaknesses?

Negative profit margin of -22.1% indicates financial instability.

• Small market capitalization of $20.0M.
• Reliance on CytoSorb for the majority of revenue.
• Limited geographic presence.

What Could Drive CTSO Stock Higher?

Clinical trial results for CytoSorb in new indications, expected in late 2026.

• Expansion of CytoSorb sales in existing markets through increased adoption by hospitals.
• Regulatory approvals for VetResQ in key veterinary markets, anticipated in 2027.
• Development and commercialization of HemoDefend blood purification platform.

What Are the Key Risks for CTSO?

Financial-distress signal — its Altman Z-Score of -12.19 sits in the distress zone (elevated bankruptcy risk).

• Competition from larger medical device companies with greater resources.
• Stringent regulatory requirements and potential delays in approvals.
• Risk of product liability claims related to medical devices.
• Dependence on key suppliers for critical components and materials.
• Fluctuations in reimbursement policies affecting the adoption of CytoSorb.

What Are the Growth Opportunities for CTSO?

• CytoSorb's potential to improve patient outcomes in sepsis cases represents a significant growth opportunity. The company can drive adoption through clinical trials demonstrating efficacy and cost-effectiveness, targeting hospitals and intensive care units globally. This expansion is ongoing as the company continues to conduct clinical trials and market the device.
• Development and Commercialization of VetResQ: The veterinary medicine market is experiencing growth, with increasing demand for advanced medical treatments for animals. VetResQ, designed for treating sepsis and other critical illnesses in animals, offers Cytosorbents a niche market opportunity. Successful commercialization depends on regulatory approvals and establishing distribution channels within the veterinary healthcare industry. The timeline for significant revenue generation is estimated within the next 2-3 years.
• Advancement of HemoDefend Blood Purification Platform: The HemoDefend platform aims to reduce contaminants in blood supplies, addressing a critical need in transfusion medicine. The market for blood purification technologies is substantial, driven by the need to prevent transfusion reactions and diseases. Securing regulatory approvals and partnerships with blood banks and hospitals are crucial for commercial success. This is a longer-term opportunity, with potential revenue impact in 3-5 years.
• Commercialization of K+ontrol for Hyperkalemia Treatment: The market for hyperkalemia treatment is growing due to the increasing prevalence of chronic kidney disease and diabetes. K+ontrol offers a potential solution for patients with life-threatening hyperkalemia. Successful commercialization depends on clinical trial results and regulatory approvals. The timeline for market entry is estimated within the next 2-4 years.
• Expansion into Organ Transplantation Support: CytoSorb's application in maintaining and enhancing the quality of solid organs for transplant represents a specialized growth area. The increasing demand for organ transplants and the need to improve organ preservation techniques drive this opportunity. Collaborations with transplant centers and demonstrating improved transplant outcomes are essential for market penetration. This is an ongoing opportunity with potential for steady growth over the next several years.

What Are CTSO's Competitive Advantages?

• Proprietary Adsorbent and Porous Polymer Technology: The company's patented technology provides a competitive advantage in blood purification.
• CytoSorb Brand Recognition: CytoSorb has established a reputation in critical care settings.
• Regulatory Approvals: Securing regulatory approvals in key markets creates barriers to entry for competitors.
• Clinical Data: Positive clinical trial results support product efficacy and adoption.

What Does CTSO Do?

Cytosorbents Corporation, founded in 1997 and headquartered in Princeton, New Jersey, is a medical device company specializing in blood purification technologies. Originally named MedaSorb Technologies Corporation, the company rebranded in May 2010 to reflect its focus on developing and commercializing products based on its proprietary adsorbent and porous polymer technology. The company's flagship product, CytoSorb, is an extracorporeal cytokine filter designed for adjunctive therapy in various critical care applications, including the treatment of sepsis, prevention of perioperative complications during cardiopulmonary bypass surgery, and enhancement of the quality of solid organs for transplant. Cytosorbents also develops VetResQ, a device tailored for veterinary use in treating sepsis and other critical illnesses in animals. Other products in development include CytoSorb-XL, an advanced version of CytoSorb, HemoDefend, a blood purification platform aimed at reducing contaminants in blood supplies, K+ontrol for treating severe hyperkalemia, and ContrastSorb for removing contrast agents from blood to reduce the risk of contrast-induced nephropathy. Additionally, the company is involved in the development of BetaSorb, DrugSorb, and DrugSorb-ATR, targeting metabolic toxins, toxic chemicals, and antithrombotic agents, respectively.

What Products and Services Does CTSO Offer?

• Develop and commercialize blood purification medical devices.
• Offer CytoSorb, an extracorporeal cytokine filter for critical care applications.
• Provide solutions for sepsis treatment, including CytoSorb and CytoSorb-XL.
• Develop VetResQ for treating critical illnesses in animals.
• Create HemoDefend, a blood purification platform for reducing blood contaminants.
• Offer K+ontrol for the treatment of severe hyperkalemia.
• Develop ContrastSorb for removing IV contrast in blood.

How Does CTSO Make Money?

• Develop, manufacture, and sell blood purification devices.
• Generate revenue through direct sales to hospitals and medical centers.
• Establish distribution partnerships for wider market reach.
• Pursue research and development to expand product applications and indications.

What Industry Does CTSO Operate In?

Cytosorbents Corporation operates in the medical device industry, specifically focusing on blood purification technologies. The industry is characterized by technological innovation, stringent regulatory requirements, and intense competition. The global blood purification market is driven by the increasing prevalence of sepsis, kidney diseases, and other critical illnesses. Cytosorbents competes with larger medical device companies and specialized blood purification firms. The company's success depends on its ability to differentiate its products through clinical efficacy and cost-effectiveness.

Who Are CTSO's Key Customers?

• Hospitals and intensive care units.
• Transplant centers.
• Veterinary clinics and animal hospitals.
• Blood banks and transfusion centers.

Cytosorbents Corporation (CTSO) Valuation Context

Valued at $20.0M, CTSO is classified as a micro-cap stock. Relative to its peer group, CTSO's quantitative score of 23/100 is below the peer average of 36/100.

CTSO Revenue & Earnings Trend

In Q2 FY2026, CTSO generated $9.6M in top-line revenue, marking a sequential increase of 8.7%. The company recorded a net loss of $4.4M, with diluted EPS of $-1.41. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CTSO averaged $-1.45 in diluted EPS.

Company Profile

Cytosorbents Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO Phillip Chan. CTSO has traded publicly since 2006.

Key Financial Metrics

Return on assets is -18.3%, showing how much profit it generates from its asset base. A current ratio of 1.09 indicates the company holds enough short-term assets to cover its near-term obligations.

Cytosorbents Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -12.19 places it in the distress zone, a signal of elevated financial risk.

Cytosorbents Corporation has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 41.2% above estimates on average.

Over the past six months, Cytosorbents Corporation insiders filed 4 SEC Form 4 transactions — 0 sales and 4 purchases. On net that is roughly 561K shares acquired (about $219K) — insiders putting money in tends to read as conviction.

CTSO Financials

CTSO Latest News

CTSO Analyst Consensus

CTSO MoonshotScore

Cytosorbents Corporation Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources